# A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis

> **NCT02504294** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 432 (actual)

## Conditions studied

- Chronic Kidney Disease (CKD)

## Interventions

- **BIOLOGICAL:** Epoetin Hospira Arm
- **OTHER:** Standard of Care Arm
- **DRUG:** IV Iron

## Key facts

- **NCT ID:** NCT02504294
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-13
- **Primary completion:** 2016-07-02
- **Final completion:** 2016-07-16
- **Target enrollment:** 432 (ACTUAL)
- **Last updated:** 2018-06-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02504294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02504294, "A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT02504294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*